CORRECTION article

Front. Oncol., 06 April 2022

Sec. Women's Cancer

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.793448

Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

  • 1. Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China

  • 2. Key Laboratory of Shengjing Hospital, China Medical University, Shenyang, China

In the original article, there was a mistake in the legend for Figure 2 and Figure 3 as published. The scale bars of Figures 2E, F, G, 3A, B were inaccurately described. The correct legends appear below.

Figure 2

Figure 3

In the original article, there was a mistake in Figure 2G as published. We found that OE2 in Figure 2G was improperly placed during the figure editing process. The corrected Figure 2 appears below.

In the original article, there was a mistake in Figure 5I as published. DAPI of MCF7 scramble p-AKT was wrongly placed. The corrected Figure 5 appears below.

Figure 5

In the original article, there was a mistake in Table 2 as published. In the process of statistical analysis, the statistical module of SPSS was wrongly selected. The corrected Table 2 appears below.

Table 2

VariablesDFS
Univariate analysisMultivariate analysis
HR (95% CI)P valueHR (95% CI)P value
Age1.073 (0.751-1.533)0.6991.261 (0.847-1.878)0.254
Menopausal status0.603 (0.423-0.860)0.0050.123 (0.025-0.615)0.011
T stage1.117 (0.771-1.619)0.5571.142 (0.674-1.934)0.621
N stage0.974 (0.669-1.417)0.8900.951 (0.525-1.723)0.869
TNM stage0.745 (0.472-1.175)0.2060.806 (0.466-1.395)0.442
Pathological type0.864 (0.602-1.239)0.4270.953 (0.551-1.650)0.864
Histological grade0.911 (0.588-1.412)0.6770.837 (0.473-1.480)0.540
ER status0.712 (0.472-1.077)0.1070.812 (0.488-1.352)0.424
PR status0.730 (0.491-1.086)0.1200.759 (0.468-1.231)0.264
HER-2 status1.593(0.912-2.781)0.1021.727 (0.961-3.102)0.068
Ki-67 status0.871 (0.585-1.295)0.4950.797 (0.497-1.279)0.347
Molecular subtype0.802 (0.380-1.695)0.5640.932 (0.431-2.016)0.858
GLYAT status1.565 (1.098-2.232)0.0130.145 (0.031-0.690)0.015

Univariate and multivariate analyses of clinicopathological risk factors for disease-free survival among breast cancer patients.

In the original article, there was an error in the results of multivariate analysis as the statistical module of SPSS was wrongly selected. A correction has been made to Results, “Lower GLYAT Expression Is Correlated With Poorer Prognosis and Malignant Clinicopathological Features in Human Breast Cancer Tissues”, paragraph 3:

“BC patients were analyzed for their GLYAT status and prognosis via Kaplan-Meier survival analysis as well as log-rank tests after being followed up for an average of 61.75 months (range, 9–77 months). We found that those with decreased GLYAT levels experienced poorer disease-free survival (DFS) (Figure 6D; P=0.012). GLYAT expression was a significant indicator of DFS rates in breast cancer patients based on univariate Cox regression analysis, demonstrating a hazard ratio (HR) of 1.565 [P<0.05; 95% confidence interval (CI) 1.098-2.232] (Table 2). Further multivariate analysis revealed that GLYAT expression was significantly related to DFS (HR, 0.145; 95% CI, 0.031-0.690; P=0.015) (Table 2) and represented an independent risk factor of prognosis for BC”.

After rediscussing the author contributions, all the authors agree to change the former co-responding author to co-author. The corrected Author Contributions Statement appears below.

The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Author contributions

SG conceived and designed the experiments as well as contributed to the writing of the manuscript. XT, NW, MJ, YZ, NM, and RW performed the experiments. GL provided the tumor tissue microarray and brief guidance about conception at the beginning of the study. XT performed clinical analysis and helped with drawing the figures. SG revised the paper. All authors contributed to the article and approved the submitted version.

Summary

Keywords

GLYAT, breast cancer, EMT, PI3K/AKT, clinicopathological features, prognosis

Citation

Tian X, Wu L, Jiang M, Zhang Z, Wu R, Miao J, Liu C and Gao S (2022) Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer. Front. Oncol. 12:793448. doi: 10.3389/fonc.2022.793448

Received

12 October 2021

Accepted

04 March 2022

Published

06 April 2022

Volume

12 - 2022

Edited and reviewed by

Zhijie Jason Liu, The University of Texas Health Science Center, United States

Updates

Copyright

*Correspondence: Song Gao,

This article was submitted to Women's Cancer, a section of the journal Frontiers in Oncology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics